CJC-1295 won't be found on pharmacy shelves in Kolbu or virtually any local market — it's a research-grade peptide supplied via a dedicated online market. This matters because CJC-1295 quality differs enormously across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor controls every quality variable. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis documenting HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. The sections below cover what Kolbu researchers need to know about sourcing, verifying, and handling CJC-1295 for scientific research use.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Kolbu researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor publish batch-specific COAs proactively? Vendors who do are operating transparently. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. For Kolbu researchers evaluating vendors with limited track records: a small initial order to verify quality before committing to research quantities is the accepted approach among experienced researchers. Price is an unreliable primary filter for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Kolbu
COA-verified · International tracking · Research grade
CJC-1295 operates outside the framework of pharmaceutical oversight — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and temperature control throughout the entire workflow. Quality CJC-1295 sourcing directly determines safety outcomes — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that verified-quality sourcing directly prevents. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
